This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi

LIVE RELEASE DATE

Friday, October 21 from 11:00 AM-12:00 PM ET.

TARGET AUDIENCE

The target audiences for the proposed HCP activity are specialty NPs and PAs, Allergists, Immunologists, ORLs/ENTs, Specialist NPs and PAs

STATEMENT OF NEED/PROGRAM OVERVIEW

Many patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who fail first-line treatment or are ineligible for systemic corticosteroids undergo functional endoscopic sinus surgery (FESS), which has high associated costs, a likelihood of recurrence, and potential complications. However, new evidence supports the efficacy, tolerability, impact on quality of life, and place in treatment of targeted biologics approved for the management of CRSwNP.

Join an expert panel of clinicians to review the underlying pathophysiology of CRSwNP and the heavy disease burden patients with recurrent nasal polyps experience. Approvals of monoclonal antibodies targeting T2 inflammation offer additional options for patients. Panelists will clarify the place of FESS and biologic agents in the treatment of CRSwNP refractory to standard treatments, of recurring nasal polyps after surgery, and in people who cannot receive systemic steroids. Enhanced partnerships between allergists and ear, nose, and throat specialists, along with greater inclusion of each patient’s voice in care, can ensure more patient-centered and effective treatment of CRSwNP.

Do you have patients with nasal polyps who could benefit from related education on the latest treatment strategies and advances? Direct your patients to MedLive.com to access the activity, “Breathe, Finally: Practical, Proactive Approaches to Receive Personalized Care for Your Nasal Polyps.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Describe the burden of disease faced by patients with recurrent NPs or those who are not eligible for systemic corticosteroids
• Summarize data documenting the efficacy and safety of new T2 inflammation targeted biologic agents, including impacts on QoL and bothersome symptoms, in people with refractory NPs and recurrent NPs after FESS, as well as those ineligible for systemic corticosteroids
• Recognize the place of biologic agents targeting T2 inflammation in the management of patients with NPs
• Describe strategies to engage patients with NPs in shared-decision making to enhance access to patient-centered care and improve patient satisfaction and QoL

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Dr. John Bosso Clinical Professor Division of Rhinology Department of Otorhinolaryngology: Head and Neck Surgery Perelman School of Medicine at The University of Pennsylvania	Research Grant: Cumberland Pharma, Optinose Advisory Boards: Novartis, Sanofi/Regeneron, GSK
Dr. Noam A. Cohen, MD, PhD Professor of Otorhinolaryngology – Head and Neck Surgery Perelman School of Medicine at The University of Pennsylvania	Owner/Co-Owner Founder/Co-Founder: 4 Sinuses LLC (consulting company) Consulting Fee: AstraZeneca, GlaxoSmithKline, OysterPoint, Sanofi/Regeneron Stock Option Holder: OysterPoint Royalty: GeneOne Life Sciences

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Carole Drexel	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Eve Wilson	Nothing to disclose
Caroline Laurendeau	Nothing to disclose
Jack Vielbig- Patient with sinus and Nasal polyps	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.

---